Neurology and Neurosurgery - Global Neurology Academy

65-80 of 455

Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
NeuroFrontiers
Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
- Michael Levy, MD, PhD
Navigating MS Diagnosis in Older Adults: Distinguishing Comorbidities and Mimics
Navigating MS Diagnosis in Older Adults: Distinguishing Comorbidities and Mimics
NeuroFrontiers
Navigating MS Diagnosis in Older Adults: Distinguishing Comorbidities and Mimics
- Le Hua, MD
Decoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
Decoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
NeuroFrontiers
Decoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
- Ryan Quigley
Timing Matters: Influenza Vaccination Response in MS Patients on Ofatumumab
Timing Matters: Influenza Vaccination Response in MS Patients on Ofatumumab
NeuroFrontiers
Timing Matters: Influenza Vaccination Response in MS Patients on Ofatumumab
Modern MS Management: Leveraging Technology to Support Brain Health
Modern MS Management: Leveraging Technology to Support Brain Health
Global Neurology Academy
Modern MS Management: Leveraging Technology to Support Brain Health
- Victoria Leavitt, PhD
- Gates B. Colbert, MD
Clemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms
Clemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms
NeuroFrontiers
Clemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms
Advances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
Advances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
NeuroFrontiers
Advances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
- Marc Haut, PhD
Transforming Alzheimer’s Care: Anti-Amyloid Therapies and Emerging Genetic Approaches
Transforming Alzheimer’s Care: Anti-Amyloid Therapies and Emerging Genetic Approaches
NeuroFrontiers
Transforming Alzheimer’s Care: Anti-Amyloid Therapies and Emerging Genetic Approaches
- Marc Haut, PhD
Addressing Barriers to MenB and MenACWY Vaccination
Addressing Barriers to MenB and MenACWY Vaccination
Global Neurology Academy
Addressing Barriers to MenB and MenACWY Vaccination
Advances in the Treatment of Neuropsychiatric Symptoms of Alzheimer's Disease: Early Recognition, Diagnosis, and Innovative Emerging Therapies
Advances in the Treatment of Neuropsychiatric Symptoms of Alzheimer's Disease: Early Recognition, Diagnosis, and Innovative Emerging Therapies
CME/CE
Advances in the Treatment of Neuropsychiatric Symptoms of Alzheimer's Disease: Early Recognition, Diagnosis, and Innovative Emerging Therapies
1.00 credit
- Marwan Sabbagh, MD, FAAN
- Alireza Atri, MD, PhD
- Christoph U. Correll, MD
1.00 credit
Evaluating MenB Vaccines Beyond the Traditional hSBA Assay
Evaluating MenB Vaccines Beyond the Traditional hSBA Assay
Global Neurology Academy
Evaluating MenB Vaccines Beyond the Traditional hSBA Assay
The Future of MS Management: Novel Agents and Clinical Approaches
The Future of MS Management: Novel Agents and Clinical Approaches
NeuroFrontiers
The Future of MS Management: Novel Agents and Clinical Approaches
- Marisa McGinley, DO
MS Relapse vs Pseudo-Relapse After Infection: COVID-19 Shows Divergent Risk Pattern
MS Relapse vs Pseudo-Relapse After Infection: COVID-19 Shows Divergent Risk Pattern
NeuroFrontiers
MS Relapse vs Pseudo-Relapse After Infection: COVID-19 Shows Divergent Risk Pattern
Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings from the MAPLE-MS Pharmacovigilance Program
Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings from the MAPLE-MS Pharmacovigilance Program
NeuroFrontiers
Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings from the MAPLE-MS Pharmacovigilance Program
Reevaluating Natalizumab Dosing in RRMS: Insights from the NOVA Trial
Reevaluating Natalizumab Dosing in RRMS: Insights from the NOVA Trial
NeuroFrontiers
Reevaluating Natalizumab Dosing in RRMS: Insights from the NOVA Trial
Recognizing MS: Understanding Symptoms and Avoiding Misdiagnosis
Recognizing MS: Understanding Symptoms and Avoiding Misdiagnosis
NeuroFrontiers
Recognizing MS: Understanding Symptoms and Avoiding Misdiagnosis

5/10